FCGR3A and ovarian neoplasm: While NK cells have been previously reported to be present within ovarian tumors [26], post hoc analysis of CD16a isoforms V158F in patients from the post hoc set found no difference with regards to farletuzumab or placebo subgroup clinical outcome.